There are currently 17 active clinical trials seeking participants for Aortic Valve Stenosis research studies. The states with the highest number of trials for Aortic Valve Stenosis participants are California, New York, Texas and Pennsylvania.
MRI in Transcatheter Aortic Valve Replacement Patients
NCT05603026
Recruiting
The hypothesis is that SEV result in superior valvular hemodynamics (more pronounced during exercise) and exercise capacity relative to BEV. Furthermore, the hypothesis is that stress CMR will be able to demonstrate differences in these hemodynamic parameters. CMR will also provide refined assessment of paravalvular leak and its impact on ventricular function and on clinical outcomes.
Gender:
ALL
Ages:
Between 18 years and 105 years
Trial Updated:
11/29/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Aortic Valve Stenosis
Register for Updates
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study
NCT06269640
Recruiting
Background: Some people have a condition in which the wall (septum) that separates the two main pumping chambers of the heart is too thick. This thick septum causes a condition called "left ventricular outflow tract obstruction" (LVOTO), which reduces blood flow out of the heart. LVOTO can cause serious heart disease; symptoms may include shortness of breath, chest pain, heart failure, or death. Researchers want to find better ways to treat LVOTO. Objective: To test a new procedure where exce... Read More
Gender:
ALL
Ages:
Between 21 years and 99 years
Trial Updated:
02/20/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Septal Hypertrophy, Mitral Valve Disease, Aortic Valve Stenosis
Register for Updates
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
Recruiting
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/19/2025
Locations: Heart Center LLC, Huntsville, Huntsville, Alabama +79 locations
Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
Register for Updates
Bicuspid Aortic Valve Replacement: Evaluation of Transcatheter Versus Surgery-Pilot Trial
NCT06817148
Recruiting
The study protocol is a randomized trial of standard of care therapies for severe aortic stenosis (AS) in patients with a bicuspid aortic valve (BAV). Namely, the therapies to which patients will be randomized will be transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), in patients deemed clinically suitable for both following heart team review. The purpose of this study is to compare the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR)... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/05/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Aortic Valve Stenosis, Bicuspid Aortic Valve
Register for Updates
Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform
NCT06099665
Recruiting
This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: Saint Luke's Health System, Kansas City, Missouri +5 locations
Conditions: Aortic Valve Stenosis, Mitral Regurgitation
Register for Updates
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
NCT05172973
Recruiting
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
09/27/2024
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +33 locations
Conditions: Aortic Valve Insufficiency, Aortic Valve Stenosis
Register for Updates
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
NCT05459233
Recruiting
Data on valve performance following ViV-TAVR has usually been obtained with the use of Doppler-echocardiography. However, some reports have shown significant discordances in the evaluation of mean transvalvular gradient between echocardiography and catheterization, with an overestimation of the real gradient with echo (vs. cath) in most cases. Thus, the incidence of procedural-device failure may be lower than that reported in the ViV-TAVR literature,
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: University of California, San Francisco, California +6 locations
Conditions: Aortic Valve Stenosis, Aortic Valve Regurgitation, Prosthesis Failure
Register for Updates
Effect of Fetal Aortic Valvuloplasty on Outcomes
NCT05386173
Recruiting
In one of the most severe congenital heart defects, hypoplastic left heart syndrome (HLHS), the left ventricle is underdeveloped and the prognosis is worse than in most other heart defects. The underdevelopment can occur gradually during fetal growth caused by a narrowing of the aortic valve. At some international centers, such fetuses are treated with a balloon dilation of the narrowed valve, but there is no scientifically sound evidence that this treatment is effective. The aim of this study... Read More
Gender:
All
Ages:
Between 23 weeks and 31 weeks
Trial Updated:
11/18/2023
Locations: Fetal Cardiovascular Program, University of California San Francisco, San Francisco, California +12 locations
Conditions: Congenital Heart Disease, Aortic Valve Stenosis, Fetal Cardiac Disorder, Hypoplastic Left Heart Syndrome
Register for Updates
Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
NCT05295628
Recruiting
The objective of the study is to evaluate the safety, effectiveness, and performance of the EMBLOK EPS during TAVR by randomized comparison with a commercially available embolic protection device. The targeted study population consists of patients meeting FDA-approved indications for TAVR with commercially available transcatheter heart valve systems. This prospective, multicenter, single-blind, randomized controlled trial will enroll up to a total of 532 subjects undergoing TAVR at up to 30 inv... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
11/07/2023
Locations: UPMC Pinnacle Harrisburg, Harrisburg, Pennsylvania
Conditions: Aortic Valve Stenosis, Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Replacement
Register for Updates
Standardized Invasive Hemodynamics for Elevated Gradients Post TAVR (DISCORDANCE TAVR)
NCT04827238
Recruiting
The DISCORDANCE TAVR study will determine the discordance between echocardiography-derived and invasive transaortic gradients, as determined by a consistent and reproducible technique (Standardized Invasive Hemodynamics) post-TAVR.
Gender:
All
Ages:
All
Trial Updated:
06/06/2023
Locations: PIMA Heart Centre, Tucson, Arizona +9 locations
Conditions: Aortic Stenosis, Aortic Valve Stenosis
Register for Updates
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
NCT05862558
Recruiting
To assess the efficacy and safety of Intravascular Lithotripsy (IVL) in subjects undergoing transfemoral TAVR in patients with severe iliac disease, prohibitive for transfemoral TAVR in patients with severe symptomatic aortic stenosis, otherwise considered for alternative access TAVR. (e.g. trans-carotid)
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/08/2023
Locations: Baylor Scott and White Heart Hospital, Plano, Texas
Conditions: Iliac Disease, Aortic Valve Stenosis
Register for Updates
Platelet Adhesion in the Pathobiology of Aortic Stenosis
NCT05550896
Recruiting
Aortic stenosis (AS) is a serious and common condition that affects 2-3% of the population >65 years of age in Western countries. It is also responsible for extraordinarily high healthcare expenditures, estimated to be over $6 billion annually,2 in part because the primary treatment for severe AS is aortic valve replacement (AVR) which is resource-intensive. Valve abnormalities are frequently recognized before AS becomes severe, or before there is need for guideline-directed procedural intervent... Read More
Gender:
All
Ages:
25 years and above
Trial Updated:
04/18/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Aortic Valve Stenosis
Register for Updates